X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Strides Arcolab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs STRIDES SHASUN LTD - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD STRIDES SHASUN LTD BIOCON LTD/
STRIDES SHASUN LTD
 
P/E (TTM) x 96.7 41.3 234.3% View Chart
P/BV x 8.2 1.0 799.1% View Chart
Dividend Yield % 0.1 1.0 14.6%  

Financials

 BIOCON LTD   STRIDES SHASUN LTD
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
STRIDES SHASUN LTD
Mar-17
BIOCON LTD/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs1,1881,275 93.2%   
Low Rs305918 33.2%   
Sales per share (Unadj.) Rs68.7389.6 17.6%  
Earnings per share (Unadj.) Rs7.628.0 27.0%  
Cash flow per share (Unadj.) Rs14.048.9 28.6%  
Dividends per share (Unadj.) Rs1.004.50 22.2%  
Dividend yield (eoy) %0.10.4 32.6%  
Book value per share (Unadj.) Rs86.3303.1 28.5%  
Shares outstanding (eoy) m600.0089.42 671.0%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x10.92.8 386.0%   
Avg P/E ratio x98.939.2 252.2%  
P/CF ratio (eoy) x53.422.4 238.3%  
Price / Book Value ratio x8.63.6 239.0%  
Dividend payout %13.216.1 82.3%   
Avg Mkt Cap Rs m447,90098,036 456.9%   
No. of employees `0006.15.8 106.0%   
Total wages/salary Rs m9,3115,881 158.3%   
Avg. sales/employee Rs Th6,705.86,005.9 111.7%   
Avg. wages/employee Rs Th1,514.21,014.0 149.3%   
Avg. net profit/employee Rs Th736.9431.2 170.9%   
INCOME DATA
Net Sales Rs m41,23434,834 118.4%  
Other income Rs m2,0621,686 122.3%   
Total revenues Rs m43,29636,520 118.6%   
Gross profit Rs m8,2916,428 129.0%  
Depreciation Rs m3,8511,872 205.8%   
Interest Rs m6152,269 27.1%   
Profit before tax Rs m5,8873,973 148.2%   
Minority Interest Rs m2130-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m1,569470 333.8%   
Profit after tax Rs m4,5312,501 181.2%  
Gross profit margin %20.118.5 109.0%  
Effective tax rate %26.711.8 225.3%   
Net profit margin %11.07.2 153.1%  
BALANCE SHEET DATA
Current assets Rs m41,48638,165 108.7%   
Current liabilities Rs m21,41330,402 70.4%   
Net working cap to sales %48.722.3 218.4%  
Current ratio x1.91.3 154.3%  
Inventory Days Days6477 82.7%  
Debtors Days Days94104 90.1%  
Net fixed assets Rs m50,66137,639 134.6%   
Share capital Rs m3,000894 335.5%   
"Free" reserves Rs m48,80826,210 186.2%   
Net worth Rs m51,80827,105 191.1%   
Long term debt Rs m17,89816,377 109.3%   
Total assets Rs m99,89781,168 123.1%  
Interest coverage x10.62.8 384.3%   
Debt to equity ratio x0.30.6 57.2%  
Sales to assets ratio x0.40.4 96.2%   
Return on assets %5.25.9 87.7%  
Return on equity %8.79.2 94.8%  
Return on capital %9.612.1 79.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05813,465 89.6%   
Fx outflow Rs m7,3484,076 180.3%   
Net fx Rs m4,7109,389 50.2%   
CASH FLOW
From Operations Rs m6,6212,881 229.8%  
From Investments Rs m-6,840-7,051 97.0%  
From Financial Activity Rs m-2,3973,382 -70.9%  
Net Cashflow Rs m-2,612-788 331.7%  

Share Holding

Indian Promoters % 40.4 27.7 145.8%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 37.8 22.2%  
FIIs % 10.7 8.6 124.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 25.9 76.8%  
Shareholders   109,995 56,241 195.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SHASUN PHARMA  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Related Views on News

BIOCON LTD Surges by 5%; BSE HEALTHCARE Index Up 1.8% (Market Updates)

Sep 25, 2018 | Updated on Sep 25, 2018

BIOCON LTD share price has surged by 5% and its current market price is Rs 701. The BSE HEALTHCARE is up by 1.8%. The top gainers in the BSE HEALTHCARE Index is BIOCON LTD (up 5.0%). The top losers are ABBOTT INDIA and J.B.CHEMICALS (down 0.3%).

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Sep 25, 2018 03:37 PM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS